Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Join Us
Values & Culture
Perks & Benefits
Explore Careers
Contact
Posters & Presentations
Product Pipeline
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
All
Poster
Presentation
July 19, 2022
Presentation
Aptose Corporate Presentation July 2022
Aptose Corporate Presentation July 2022:
View Presentation
June 27, 2022
Presentation
Aptose Corporate Presentation June 2022
Aptose Corporate Presentation June 2022:
View Presentation
June 2, 2022
Presentation
Aptose KOL Event and Clinical Update
Aptose KOL Event and Clinical Update:
View Presentation
March 15, 2022
Presentation
Aptose Corporate Presentation March 2022
Aptose Corporate Presentation March 2022:
View Presentation
December 13, 2021
Presentation
Aptose Corporate Update at ASH 2021
Aptose Corporate Update at ASH 2021:
View Presentation
December 13, 2021
Presentation
2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML
2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML:
View Presentation
June 11, 2021
Presentation
Aptose Corporate Update at EHA 2021
Aptose Corporate Update at EHA 2021:
View Presentation
December 6, 2020
Presentation
Aptose Corporate Update at ASH 2020
Aptose Corporate Update at ASH 2020:
View Presentation
April 27, 2020
Presentation
2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL
2020 AACR Presentation - Early clinical findings from a Phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with R/R CLL/SLL or NHL:
View Presentation
Previous
1
2
3
Next